Gabapentin/Naproxen

加巴喷丁/萘普生

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGabapentin/Naproxen

Drug Alias Name萘普生/加巴喷丁Naproxen/Gabapentingabapentin + naproxen combination

ClassificationSmall molecules

Mechanisms of ActionCyclooxygenases inhibitorsVoltage-gated calcium channel alpha2/delta subunit 2 blockersVoltage-gated N-type calcium channel alpha-1B subunit blockers

TargetsVoltage-gated N-type calcium channel alpha-1B subunitVoltage-gated calcium channel alpha2/delta subunit 2Cyclooxygenases

Therapy Area/IndicationsToothacheOsteoarthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Naproxen Gabapentin

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsToothacheOsteoarthritis

Other Information

ATC CodeN/A